



CONVERSATION RECORD

NAME OF PERSON(S)/TITLE CONTACTED OR IN CONTACT WITH YOU James York; Frank Plastini; Todd Heiskell; Chris Troha; Mike Levy		DATE OF CONTACT 12/13/2017	TYPE OF CONVERSATION <input checked="" type="checkbox"/> E-MAIL <input type="checkbox"/> TELEPHONE <input type="checkbox"/> INCOMING <input checked="" type="checkbox"/> OUTGOING	
E-MAIL ADDRESS chris.troha@aon.com - 312-381-4590 michael.levy@sofie.com - 412-716-6900		TELEPHONE NUMBER 312-381-4590		
ORGANIZATION Sofie Network Inc. d/b/a Sofie	DOCKET NUMBER(S) 030-38113			
LICENSE NAME AND NUMBER(S) 45-25221-05	MAIL CONTROL NUMBER(S) 591378			

SUBJECT
Additional Information Request concerning the licensee's request to update decommissioning financial assurance instruments following Transfer of Control from Zevacor Pharma

SUMMARY AND ACTION REQUIRED (IF ANY)
This record concerns the licensee's June 30, 2016 Decommissioning Funding Plan (DFP; NRC Accession No. ML16183A318), submitted to meet requirements listed in Title 10 of the *Code of Federal Regulations* Section 30.36(e). It also concerns the licensee's (via Zevacor Pharma) September 5, 2017 Surety Bond (SB) and September 20, 2017 Rider (ML17264A971). The conversation was documented on 7/31/2018 by then-MLB-reviewer J. Bishop, to note status of the review.

Upon review, then-MLB-reviewer J. Bishop had noted that the DFP - submitted by predecessor entity Zevacor Pharma - was consistent with cost estimate tables provided in previous cost estimates which had been approved. Accordingly, no additional information was needed from the licensee to complete our review of the DFP, as of the date of the referenced conversation.

Upon review, however, we noted that changes needed to be made to the SB and that an STA and CFA were required to be provided. In the conversation then-MLB-reviewer J. Bishop discussed those changes and received confirmation from Mr. York that updates would be provided by 12/22/2017. No responses were received from either Mr. York or Mr. Plastini at Zevacor; neither could be reached as of February 2018. Mr. Heiskell, the RSO, indicated that neither Mr. York nor Mr. Plastini were still with the company; he referred the reviewer to Chris Troha of Aon Risk Solutions who is the Zevacor contact for the SB. Mr. Troha referred the reviewer to Mike Levy who is the Corporate RSO and the Sofie contact for the Sofie FA instruments.

The review is ongoing, including to request and receive updated financial assurance instruments.

NAME OF PERSON DOCUMENTING CONVERSATION
Sara A. Forster, M.S., Health Physicist, Materials Licensing Branch, DNMS, RIII office, sara.forster@nrc.gov

SIGNATURE 	DATE OF SIGNATURE 07/29/2019
----------------------	--